Clinical trial
A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis
NCT00067080 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2003
- Completion date
- Not reported
- Enrollment
- 195 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.